SavedAdd your journal

Journals / Haseki Tıp Bülteni / 2020 / Cilt: 58 - Sayı: 1

Efficacy of Low Dose Valganciclovir Prophylaxis for Cytomegalovirus Infection in Kidney Transplantation

Böbrek Naklinde Sitomegalovirüs Enfeksiyonu için Düşük Doz Valgansiklovir Profilaksisinin Etkinliği

Ümit ÖZÇELİK
Nadir ALPAY
Eryiğit EREN
Bora USLU
Ahmet Cem YARDIMCI
Pages
27–32
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We recommend low-dose valganciclovir due to low incidence of CMV infection found in our study.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Valganciclovir is the preferred drug for chemoprophylaxis for the prevention of cytomegalovirus (CMV) infection in kidney recipients.
📊
Key Findings & Data:Low-dose (450 mg/day) valganciclovir use is gaining popularity because standard dose (900 mg/day) has negative effect on renal function and side effects such as leukopenia.
💡
Conclusion & Impact:We recommend low-dose valganciclovir due to low incidence of CMV infection found in our study.
🔬Design:Research Article
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: Valganciclovir is the preferred drug for chemoprophylaxis for the prevention of cytomegalovirus (CMV) infection in kidney recipients. Low-dose (450 mg/day) valganciclovir use is gaining popularity because standard dose (900 mg/day) has negative effect on renal function and side effects such as leukopenia. We present our results with low-dose valganciclovir prophylaxis in kidney recipients. Methods: One hundred thirteen kidney transplant recipients who were operated between 1 December 2017 and 1 September 2018 in İstanbul Aydın University Faculty of Medicine, Training and Research Hospital and İstinye University Training and Research Hospital were retrospectively evaluated. Demographic data, preoperative CMV status, incidence of CMV infection and leukopenia rates were recorded. Results: A total of 113 patients (46 women, 67 men) with a mean age of 42.85 years were evaluated. All the recipients and donors were preoperative CMV IgG-positive. The mean follow-up was seven (6-13) months. In this period, only two (1.76%) CMV infection occurred and treated with intravenous ganciclovir. There were no complications due to CMV infection. There was no leukopenia related with valganciclovir. Conclusion: This study showed that low-dose valganciclovir is an effective prophylaxis for CMV infection in kidney transplantation with CMV-positive donors and recipients. We recommend low-dose valganciclovir due to low incidence of CMV infection found in our study.

Özet

Amaç: Valgansiklovir böbrek nakli hastalarında Sitomegalovirüs (CMV) profilaksisi için tercih edilen ilaçtır. Standart dozun (900 mg/gün) böbrek fonksiyonlarına olan olumsuz etkisi ve lökopeni yan etkisi nedeniyle düşük doz (450 mg/gün) Valgansiklovir kullanımı giderek yaygınlaşmaktadır. Bu çalışmada düşük doz Valgansiklovirin etkinliği ile ilişkili sonuçlarımızı sunduk. Yöntemler: 01 Aralık 2017 ile 01 Eylül 2018 tarihleri arasında İstanbul Aydın Üniversitesi Tıp Fakültesi, Uygulama ve Araştırma Merkezi Hastanesi ve İstinye Üniversitesi Tıp Fakültesi, Uygulama ve Araştırma Merkezi Hastaneleri’nde yapılmış olan böbrek nakli hastaları incelendi. Hastaların demografik bulguları, preoperatif CMV durumları, postoperatif CMV ve lökopeni insidansı değerlendirildi. Bulgular: Ortalama yaşı 42,85 olan toplam 113 hasta (46 kadın, 67 erkek) dahil edildi. Hastaların tümünün preop CMV IgG (+), donörlerin de tümünün preop CMV IgG (+) idi. Ortalama takip süresi 7 ay (6-13 ay) idi. Bu süreçte iki hastada CMV hastalığı (%1,76) gelişti. Her iki hasta da intravenöz gansiklovir ile tedavi edildi. CMV’ye bağlı herhangi bir komplikasyon gelişmedi. Hiçbir hastada valgansiklovire bağlı lökopeni görülmedi. Sonuç: Bu çalışmada düşük doz Valgansiklovirin donör ve alıcı CMV pozitif olan böbrek nakli alıcılarında CMV profilaksisi için etkin olduğu görülmüştür. Biz de çalışmamızda postoperatif CMV insidansının düşük olması nedeniyle düşük doz Valgansiklovir kullanımını öneriyoruz

🔖

Cite This Article

ÖZÇELİK, Ü., ALPAY, N., EREN, E., USLU, B., YARDIMCI, A. C. (2020). Efficacy of Low Dose Valganciclovir Prophylaxis for Cytomegalovirus Infection in Kidney Transplantation. Haseki Tıp Bülteni, Cilt: 58 - Sayı: 1, 27–32. https://ajindex.com/articles/267784

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Lee JH, Hwang SD, Song JH, et al. Efficacy of Ultralow-Dose Valganciclovir Chemoprophylaxis for Cytomegalovirus Infection in ABO-Incompatible Kidney Transplantation Recipients. Transplant Proc 2018;50:2485-8.
  2. Stevens DR, Sawinski D, Blumberg E, Galanakis N, Bloom RD, Trofe-Clark J. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis. Transpl Infect Dis 2015;17:163-73.
  3. Posadas Salas MA, Taber DJ, Chua E, Pilch N, Chavin K, Thomas B. Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation. Transpl Infect Dis 2013;15:551-8.
  4. Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. Pharmacotherapy 2004;24:1323-30.
  5. Avidan YP, Paul M, Rahamimov R, et al. Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation. J Infect 2008;57:236-40.
  6. Parreira L, Bruges M, Gaspar A, Weigert A, Machado D. Prevention of cytomegalovçirus disease in renal transplantation: single-center experience. Transplant Proc 2009;41:877-9.
  7. Kalil AC, Mindru C, Florescu DF. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. Clin Infect Dis 2011;52:313-21.
  8. Welker H, Farhan M, Humar A, Washington C. Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days. Transplantation 2010;90:1414-9.
  9. Wiltshire H, Paya C, Pescovitz M, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005;79:1477-83.
  10. Czock D, Scholle C, Rasche FM, Schaarschmidt D, Keller F. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther 2002;72:142-50. Wéclawiak H, Kamar N, Mengele C, et al. Cytomegalovirus prophylaxis with valganciclovir in cytomegalovirus-seropositive kidney-transplant patients. J Med Virol 2008;80:1228-32.
  11. Boivin G, Goyette N, Gilbert C, et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 18